Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon in Major Depressive Disorder
NCT01428661Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tasimelteon in major depressive disorder (MDD), sponsored by Vanda Pharmaceuticals Inc.. Started Sep 2011; status: completed.
02
Drugs
tasimelteon
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01428661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01428661.